Knowledge graph · Drug
Tovorafenib
small molecule
- Identifier
- CI-DRUG-00000599
- Entity page
- /drug/tovorafenib ↗
- Edges
- 63
- Neighbours
- 22 cancers3 genes4 variants10 trials7 approvals
- Drawn
- 46 of 46 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Tovorafenib approved for …APPROVED_FOR8 of 7 | ||||||||
| → approved for | Gliomasubtype | supports | mesh_therapeutic_area | Glioma | 1 | Regulatory | ema | graph → |
| → approved for | EMA · EU · 2026Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2) | |||||||